Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Voltaren
Drug ID BADD_D02367
Description Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin].[A180796] The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).[L7360]
Indications and Usage For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D11AX18; M01AB05; M02AA15; S01BC03
DrugBank ID DB00586
KEGG ID D00904
MeSH ID D004008
PubChem ID 5018304
TTD Drug ID D0TG1H
NDC Product Code 50090-2787; 55700-675; 58602-603; 70518-0871; 11014-0415; 55700-735; 57896-142; 58602-602; 65162-911; 68788-7270; 17856-0833; 69344-203; 76420-012; 62512-0051; 42291-256; 58602-601; 71335-0371; 80425-0056; 50090-3316; 11014-0416; 63187-762; 69238-2053; 0378-8750; 45865-986; 50268-237; 70518-1333; 50090-4621; 69344-204; 73480-242; 48589-0002; 65162-833
Synonyms Diclofenac | Diclophenac | Dicrofenac | Dichlofenal | Diclofenac Sodium | Sodium Diclofenac | Diclofenac, Sodium | Diclonate P | Feloran | Voltarol | Novapirina | Orthofen | Ortofen | Orthophen | SR-38 | SR 38 | SR38 | Voltaren | Diclofenac Potassium | GP-45,840 | GP 45,840 | GP45,840
Chemical Information
Molecular Formula C14H10Cl2NNaO2
CAS Registry Number 15307-79-6
SMILES C1=CC=C(C(=C1)CC(=O)[O-])NC2=C(C=CC=C2Cl)Cl.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityCytochrome P450 2C9P11712T1924410027798; 10027801; 10064567
HepatotoxicityCytochrome P450 3A4P08684T3784810027798; 10027801; 10064567
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug ineffective08.06.01.006--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Ear pain04.03.01.003--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Eczema23.03.04.006--
Encephalopathy17.13.02.001--
Endophthalmitis11.01.06.003; 06.04.05.009--
Enterocolitis haemorrhagic24.07.02.006; 07.08.01.007--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Erythema of eyelid23.03.06.006; 06.04.04.003--Not Available
Eye allergy10.01.03.028; 06.04.05.010--Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 13 Pages